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SUMMARY
Heterozygousmutations in the glucocerebrosidase gene (GBA) represent the strongest common genetic risk factor for Parkinson’s disease
(PD), the second most common neurodegenerative disorder. However, the molecular mechanisms underlying this association are still
poorly understood. Here, we have analyzed ten independent induced pluripotent stem cell (iPSC) lines from three controls and three
unrelated PD patients heterozygous for the GBA-N370S mutation, and identified relevant disease mechanisms. After differentiation
into dopaminergic neurons, we observed misprocessing of mutant glucocerebrosidase protein in the ER, associated with activation of
ER stress and abnormal cellular lipid profiles. Furthermore, we observed autophagic perturbations and an enlargement of the lysosomal
compartment specifically in dopamine neurons. Finally, we found increased extracellular a-synuclein in patient-derived neuronal culture
medium, which was not associated with exosomes. Overall, ER stress, autophagic/lysosomal perturbations, and elevated extracellular
a-synuclein likely represent critical early cellular phenotypes of PD, which might offer multiple therapeutic targets.
INTRODUCTION
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder, characterized by the preferen-
tial degeneration of dopamine neurons in the substantia
nigra pars compacta (SNpc). Heterozygous mutations in
the glucocerebrosidase gene (GBA) encoding the lysosomal
enzyme GCase represent the strongest common genetic
risk factor for PD (Sidransky et al., 2009) and have also
been associated with other related Lewy body disorders
(Goker-Alpan et al., 2006); however, the underlyingmolec-
ular mechanisms are still poorly understood.
The association of GBA with PD first emerged from clin-
ical studies that demonstrated that relatives of patients
with Gaucher’s disease (GD), a lysosomal storage disease
caused by homozygous GBA mutations, had an increased
incidence of PD (Goker-Alpan et al., 2004). More recent
studies exploring the pathogenic role of homozygous GBA
mutations in GD have highlighted a role of GCase in mito-
chondria function, a-synuclein aggregation, and autopha-
gic machinery (Mazzulli et al., 2011; Sardi et al., 2011).
GCase pathology in the context of heterozygousGBAmuta-
tions in PD have been addressed in recent postmortem
(Gegg et al., 2012) and patient fibroblast (McNeill et al.,
2014) studies, and recently in a PDpatient humanneuronal
model (Scho¨ndorf et al., 2014). Overall, mutations in GBA
and in LRRK2, also known to play a role in regulating auto-
phagy (Alegre-Abarrategui et al., 2009), have emphasized
the role for the autophagic/lysosomal pathway as central
to the pathogenesis of PD (Tofaris, 2012).
Human induced pluripotent stem cells (iPSCs) derived
from patients carrying disease-associated alleles retain the
genetic background likely to include disease-permissive ge-
netic modifiers and can be differentiated into highly phys-
iological models of specific cell types to study cellular
mechanisms of disease (Kiskinis and Eggan, 2010). Within
this paradigm, iPSCs can be differentiated into functional
midbrain dopamine neurons to provide a powerful tool
to study the genetic contribution to PD (Hartfield et al.,
2012). We have previously developed a highly physiolog-
ical cellular model of differentiated midbrain dopamine
neurons that express key dopaminergic markers, exhibit
dopamine synthesis, release, and re-uptake, and show
autonomous pace-making and spontaneous synaptic activ-
ity (Hartfield et al., 2014).
Here we study the impact of the common GBA-N370S
mutation on the phenotype of patient-specific dopami-
nergic neuronal cultures differentiated from iPSC lines
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derived from patients with PD and identify deficits in pro-
tein homeostasis. Our results suggest that the heterozygous
GBA-N370S mutation leads to a cellular gain of function,
shown by misprocessing of misfolded GCase protein in
the ER resulting in ER stress upregulation and autopha-
gic/lysosomal dysfunction leading to an enlargement of
the lysosomal compartment in individually identified
vulnerable dopamine neurons. Together, these deficits
lead to increased release of extracellular a-synuclein from
GBA-N370S PD human iPSC-derived dopamine neuron
cultures, which we show is not associated with exosomes.
We propose that the combination of these disturbances im-
pairs protein homeostasis in dopamine neurons contrib-
uting to their preferential vulnerability in PD. These data
highlight the early pathogenic relevance of GCase function
in the autophagic/lysosomal pathway in PD, and may
explain the higher risk for heterozygous GBA-N370Smuta-
tion carriers to develop PD.
RESULTS
Generation of Human iPSCs
PDpatients and controls from theDiscovery clinical cohort
established by the Oxford Parkinson’s Disease Centre
(OPDC) were screened for the presence of GBA-N370S het-
erozygous mutation (Figure S1A). We then generated and
characterized 22 human iPSC clonal lines from fibroblasts
obtained from three unrelated PD patients carrying a
GBA-N370S heterozygous mutation and three healthy con-
trol individuals (Table S1). Detailed characterization of all
PD lines used in this study is shown in Figures S1 and S2.
Characterization of lines from two of the control individ-
uals has been published previously (Control-2, vanWilgen-
burg et al., 2013; Control-1, Hartfield et al., 2014). All iPSC
lines displayed embryonic stem cell-like morphology and
expressed pluripotency-associated proteins (TRA-1-60,
SSEA-4, and Nanog; Figure S1B). Silencing of retroviral
transgenes upon establishment of pluripotency was
confirmed by qRT-PCR (Figure S1C), and Sendai virus-re-
programmed lines were checked for clearance of the exog-
enous genes by RT-PCR (Figure S1D). Pluripotency was also
assessed using the PluriTest, which is based upon analysis
of transcriptome data from iPSCs and human embryonic
stem cells and compares gene expression with a large refer-
ence set of genome-wide profiles frommultiple cell and tis-
sue types (Mu¨ller et al., 2011). Accordingly, all lines used
were classified as fully reprogrammed and pluripotent (Fig-
ure S1E). Genome integrity was confirmed by Illumina
SNP arrays (Figure S2) providing detailed resolution of
genome integrity compared with traditional karyotyping
or M-FISH. The SNP datasets also enabled confirmation
that the iPSC lines derived from the expected fibroblast
line. The SNP datasets and the Illumina HT12v4 transcrip-
tome array results have been deposited in GEO: GSE53426.
Characterization of Dopaminergic Neuronal Cultures
In order to study the effect of the heterozygousGBA-N370S
mutation in the context of PD, iPSCs were differentiated
into dopaminergic neuronal cultures (Figure 1A). A total
of ten different iPSC clonal lines from three control indi-
viduals and three PD patients carrying a GBA-N370S het-
erozygous mutation were differentiated into dopaminergic
neuronal cultures, as described previously (Hartfield et al.,
2014), with minor modifications. Briefly, embryoid bodies
prepared from iPSCs were plated in the presence of SMAD
signaling inhibitors (Noggin and SB431542) to initiate
neuronal induction, together with CHIR99021 (a potent
canonical WNT signaling activator), sonic hedgehog
(SHH), and FGF8a for midbrain floor plate induction. By
day 20, visible neural rosette structures were manually
dissected and re-plated for differentiation into dopami-
nergic neurons with ascorbic acid, cAMP, brain-derived
neurotrophic factor, and glial cell line-derived neurotro-
phic factor for 15 days. All lines successfully differentiated
into dopaminergic neuronal cultures (Figure 1B). The dif-
ferentiation efficiency, assessed by b-3 tubulin and TH
expression using immunofluorescence, was similar across
the genotypes used in the study (Figure S3). RT-PCR anal-
ysis demonstrated that differentiated dopaminergic cul-
tures expressed the floor plate markers FOXA2 and
LMX1A, in addition to the mature dopaminergic neuron
markers EN1 and NURR1, while the level of the pluripo-
tency marker OCT4 was much reduced on differentiation
(Figure 1C). We confirmed the co-expression of TH with
the floorplate marker FOXA2, the marker of the A9 do-
paminergic neurons susceptible in PD GIRK2, and the
post-mitotic midbrain neuronal marker PITX3, further
confirming the mature midbrain identity of the differ-
entiated dopaminergic neurons (Figure 1C). We have
previously confirmed the highly mature, functional dopa-
minergic phenotype in neurons derived from iPSCs using
this protocol (Hartfield et al., 2014). Neurons exhibit the
correct pharmacological and physiological characteristics
expected of mature dopamine neurons, including ex-
pression of a wide range of midbrain markers, dopamine
synthesis and uptake, spontaneous slow autonomous
Ca2+ pace-making activity, and spontaneous synaptic activ-
ity at 5–10 Hz, typical of dopamine neurons of the substan-
tia nigra pars compacta (Hartfield et al., 2014).
GBA-N370S Leads to Aberrant GCase Post-translation
Modification and Abnormal Lipid Profiles
Once we had established a human dopaminergic neuronal
culture model consistent between different lines from
multiple individuals, we next determined the effect of the
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heterozygousGBA-N370Smutation on GCase protein level
in the GBA-N370S PD lines. In addition to the expected
60 kDa isoform corresponding to mature GCase, we
observed an extra isoform of apparently higher molecular
weight only in dopaminergic neuronal cultures derived
from GBA-N370S PD patients, which represented up to
50% of total GCase in these cultures (Figure 2A). This
N370S-specific isoform was sensitive to treatment with
EndoH, which yielded a third, lower molecular weight iso-
form (Figure 2B). This demonstrates that a proportion of
GCase in the N370S GBA cell lines had retained high-
mannose oligosaccharides, indicating failure to be pro-
cessed in the Golgi, likely because of retention in the ER.
In GBA-N370S-derived dopaminergic neuronal cultures,
this EndoH-sensitive GCase isoform was significantly
more abundant, representing around 20% of total GCase
(Figure 2B). Samples were further treated with PNGase F
to remove both high-mannose and complex N-linked gly-
cans, and under these conditions no significant differences
were observed in GCase protein levels between N370S
mutant and control dopaminergic neuronal cultures (Fig-
ure 2C). Overall, these results indicate that the GBA-
N370S mutation likely results in retention in the ER as a
result of disrupting the structure and/or folding of the pro-
tein, without affecting the total amount of GCase.
LIMP2 is a GCase-specific lysosomal receptor (Reczek
et al., 2007), which has been associated with PD risk (Do
et al., 2011). In dopaminergic neuronal cultures derived
from GBA-N370S PD patients, we observed increased
LIMP2 protein expression compared with controls,
although there was inter-individual variation between
the GBA-N370S PD lines (Figure 2D). This result supports
a role for LIMP2 in trafficking ER-retained mutant GCase
from the ER to the lysosome (Reczek et al., 2007).
We next quantified the GCase substrate lipids in GBA-
N370S PD dopaminergic cultures. No GlcCer accumulation
was observed in patient cells, as measured by mass spec-
trometry quantification of individual species normalized
to the ceramide precursor (Figure S4A). Notably, the distri-
bution of GlcCer species was markedly different in GBA-
N370S PD dopaminergic cultures compared with controls,
with a 30% reduction for C20:0 GlcCer and a 65% in-
crease of C16:0 andC24:0 species (Figure 2E). Overall, these
Figure 1. Generation and Characterization of iPSC-Derived
Dopaminergic Neuronal Cultures
(A) Schematic overview of conditions used for differentiation of
iPSCs into dopaminergic neuronal cultures, with bright field rep-
resentations of cells at several stages of differentiation (scale bar,
50 mm).
(B) Immunohistochemistry representation of differentiated dopa-
minergic neuronal cultures at day 35 showing high expression
levels for the neuronal marker b-3 tubulin (red), the dopaminergic
neuron marker TH (green), and DAPI (blue).
(C) RT-PCR analysis showed reduced expression of the pluripotency
marker OCT4 and increased expression of floor plate markers (FOXA2
and LMX1A) and mature dopaminergic markers (EN1 and NURR1) in
differentiated dopaminergic neuronal cultures (DAn) versus un-
differentiated (iPS). Immunofluorescence analyses also confirmed
the co-expression of TH with FOXA1, GIRK2, and PITX3 (scale bar,
50 mm). Results are representative of at least three independent
differentiation experiments performed in triplicate per cell line.
See also Figures S1–S3.
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data indicate that the GBA-N370S heterozygous mutation
results in abnormal lipid profiles not previously reported.
ER Stress and Autophagic Disturbances in GBA-N370S
Dopaminergic Neuronal Cultures
Accumulation of misfolded proteins in the ER can overload
the cellular capacity for protein re-folding and induce ER
stress, leading to activationof theunfoldedprotein response
(UPR) (Høyer-Hansen and Ja¨a¨ttela¨, 2007). Analysis of the
two ER-resident chaperones, Bip/GRP78 and calreticulin,
revealed significant upregulation in GBA-N370S dopami-
nergic neuronal cultures when compared with control-
derived dopaminergic cultures (Figure 3A). Upregulation of
additional UPR mediators, PDI, calnexin, and IRE1alpha,
confirmed UPR activation (Figures 3B–3D), although cleav-
age of XBP1 mRNA was not observed (Figure S4B). XBP1
splicing might not be a crucial transducer in this context
as it has been previously detected in the brain in only one-
third of GBAmutant PD patients (Gegg et al., 2012).
Since ER stress can result in autophagic disturbances (Yor-
imitsu et al., 2006) through the accumulation of misfolded
proteins (Høyer-Hansen and Ja¨a¨ttela¨, 2007), we examined
the autophagosome content in our cultures by quantifying
the levels of LC3B-II and LC3 puncta (Klionsky et al., 2012).
LC3B-II, the lipidated form of the autophagosome
marker LC3/Atg8, was significantly increased in GBA-
N370S-derived dopaminergic neuronal cultures reflecting
increased levels of autophagosomes (Figure 4A). This in-
crease in LC3B-II was supported by immunofluorescence
analysis that confirmed an increased number of LC3+
puncta in dopamine neurons in GBA-N370S compared
with controls (Figure 4B). Furthermore, beclin1, a key regu-
lator of autophagy used to study autophagosome forma-
tion, was found increased in GBA-N370S dopaminergic
neuronal cultures from two patients, consistent with an
autophagic perturbation (Figure 4C).
Impaired Lysosomal Degradation in GBA-N370S
Dopaminergic Neurons
Accumulation of autophagosomes can also reflect a defect
in lysosomal clearance (Klionsky et al., 2012). Since the
GBA-N370S mutation is located in the catalytic domain of
GCase (Wei et al., 2011), we determined the impact of the
heterozygous GBA-N370S mutation on the activity of this
lysosomal enzyme. Dopaminergic neuronal cultures from
GBA-N370S PD patients had significantly reduced GCase
activity (50%decrease)when comparedwith control indi-
viduals (Figure 5A). Since reduced GCase activity could
impair the overall lysosomal degradation capacity of dopa-
mine neurons, we analyzed the levels of p62/SQSTM1 that
reflect autophagic-mediated degradation (Klionsky et al.,
2012). p62 protein levels were increased specifically in
GBA-N370S dopaminergic neuronal cultures (Figure 5B),
which supports a defect of these cells in the clearance of
autophagic vacuoles. To follow up the findings from GBA-
N370S cultures, we next comparedGBA-N370S and control
dopamine neurons for ultrastructural alterations by elec-
tronmicroscopy (EM), specifically in identified TH-positive
neurons. We found an accumulation of electron-dense
debris within lysosomal structures in GBA-N370S mutant
dopaminergic neurons in TH immunogold-labeled cells,
(Figures 5C–5E), which likely represents undegraded cargo
found in GBA-N370S dopamine neurons.
Enlarged Lysosomal Compartment in GBA-N370S
Dopaminergic Neurons
Following the previous observations suggesting impaired
lysosomal degradation, the lysosomal compartment was
analyzed in more detail. Dopaminergic neuronal cultures
derived from GBA-N370S PD patients showed increased
expression of the lysosomal markers LAMP1 (Figure 6A)
and LAMP2A (Figure 6B) when compared with cultures
derived from controls. The levels of cathepsin D, a major
Figure 2. Aberrant GCase Post-translation Modification in Heterozygous GBA-N370S PD Dopaminergic Neuronal Cultures
Representative western blot for differentiated dopaminergic neuronal cultures demonstrates the presence of two isoforms (gray and black
arrows) for GCase protein specific for GBA-N370S cultures.
(A) Quantification of GCase isoforms by western blot (as percentage of total GCase) confirms the higher molecular weight isoform (black
bars) to be specific to GBA-N370S dopaminergic neuronal cultures, representing up to 50% of total GCase levels.
(B) The GCase top isoform was sensitive to EndoH treatment shifting to a lower size band (blue arrow). Quantification of the EndoH-
sensitive band represented as a percentage of total GCase for the respective line. Student’s t test; *p < 0.0001. PD-S#1 corresponds to a
sporadic PD sample run but not analyzed further in this study.
(C) No change of total GCase expression levels after PNGase F treatment. Representative western blot and quantification of GCase is shown.
Student’s t test; not significant.
(D) Increased LIMP2 protein levels in heterozygous GBA-N370S PD dopaminergic cultures. Student’s t test; *p < 0.005. In each case, data
represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in triplicate.
(E) Analysis of different GlcCer species (C16:0, C18:0, C20:0, C22:0, C23:0, C24:0, C24:1, C24:0) as a percentage of total GlcCer shows
a difference in the distribution of GlcCer species in GBA-N370S PD dopaminergic cultures compared with controls. Each bar represents
the mean ± SEM of independent differentiated lines: three control and three GBA-N370S PD done in triplicate (n = 3). Student’s t test;
***p < 0.005; ****p < 0.0001.
See also Figure S4A.
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Figure 3. ER Stress Upregulation in Heterozygous GBA-N370S Dopaminergic Neuronal Cultures
(A) Representative western blot and quantification shows increased protein levels of the ER chaperones Bip and calreticulin.
(B–D) Representative western blot and quantification of expression of further ER stress markers, namely PDI (B), calnexin (C), and
IRE1a (D).
In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each
analyzed in triplicate. Student’s t test; *p < 0.0001. PD-S#1 corresponds to a sporadic PD sample run but not analyzed further in this study.
See also Figure S4B.
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lysosomal enzyme involved in a-synuclein degradation
(Sevlever et al., 2008) and associated with GCase defi-
ciency (Vitner et al., 2010), was also found increased in
dopaminergic neuronal cultures from GBA-N370S patients
(Figure 6C).
The enlarged lysosomal compartment was confirmed by
EM, which demonstrated a 2-fold increase in the num-
ber of lysosomes in TH immunogold-labeled cells (Figures
6D and 6E). Furthermore, the area occupied by lysosomal
organelles within TH-positive neurons detected by EM
was increased by 2.5-fold in GBA-N370S cells compared
with controls (Figures 6D and 6F), suggesting an en-
largement of the lysosomal compartment. EM data also
highlighted that the enlargement of the lysosomal com-
partment was specific to TH-positive dopaminergic neu-
rons, as no differences were found in TH-negative cells
(Figures S5A and S5B), emphasizing the importance of
studying a disease-relevant cell type. The enlarged lyso-
somal compartment may reflect impaired lysosomal
degradation capacity in dopamine neurons, which was
not altered in TH-negative cells. GBA-N370S dopami-
nergic cultures were still capable of responding efficiently
to situations of increased autophagic demand, as demon-
strated by increased lysosomal numbers under starvation
conditions determined by EM analysis (Figure S5C). Treat-
ment with the V-ATPase inhibitor bafilomycin A1 also re-
sulted in increased number of lysosomes in TH-positive
neurons, which indicates that the process of lysosomal
Figure 4. Autophagic Disturbances in Heterozygous GBA-N370S PD Dopaminergic Neuronal Cultures
(A) Representative western blot analysis and quantification showing increased LC3B-II protein levels. Student’s t test; *p < 0.0001.
(B) Increased number of LC3+ puncta in TH+ cells. Immunofluorescence staining for LC3B (green) in dopaminergic TH-positive neurons
(red) in control and PD patient dopaminergic neuronal cultures (scale bar, 20 mm). Student’s t test; *p < 0.0001.
(C) Representative western blot and quantification of Beclin1 protein levels in differentiated dopaminergic cultures. Student’s t test;
*p < 0.05. In each case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line
each analyzed in triplicate.
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biogenesis is still inducible in GBA-N370S dopaminergic
cultures (Figure S5C).
Increased Extracellular a-Synuclein in GBA-N370S
Dopaminergic Neuronal Cultures
Accumulation of a-synuclein is the characteristic patholog-
ical marker of PD and can result from defective cellular
clearance mechanisms. a-Synuclein is degraded by multi-
ple pathways including autophagy and the autophagy-
lysosome pathway (Cuervo et al., 2004), and a-synuclein
levels have been shown to be altered in response to phar-
macologically induced autophagic impairments (Klucken
et al., 2012) and ER stress (Hoepken et al., 2008). Analysis
of the intracellular a-synuclein content in dopaminergic
neuronal cultures from GBA-N370S PD showed no differ-
ences when compared with controls (Figure 7A). However,
recent reports have shown that impairments of the auto-
phagic machinery can affect the release of a-synuclein in
Figure 5. Impaired Lysosomal Degrada-
tion Capacity in Heterozygous GBA-
N370S PD Dopamine Neurons
(A) GCase enzyme activity in differentiated
dopaminergic neuronal cultures was
reduced to 50% when compared with con-
trols. Student’s t test; *p < 0.0001.
(B) Increased p62 protein levels in hetero-
zygous GBA-N370S dopaminergic cultures
when compared with controls. Representa-
tive western blot analysis and respective
quantification. In each case, data represent
the mean ± SEM from performing at least
three independent differentiation experi-
ments per line each analyzed in triplicate.
Student’s t test; *p < 0.0001.
(C) Electron micrographs showing repre-
sentative examples of undegraded cargo
observed within lysosomal structures in TH
immunogold-positive GBA-N370S-derived
neurons. Arrows indicate LAMP1 positive
structures of the lysosomal pathway; ar-
rowheads indicate TH immunogold (5 nm).
Scale bar, 200 nm.
(D) Quantification shows increased number
of lysosomes with undegraded cargo per TH+
cell in GBA-N370S cultures compared with
controls. Data represent the mean ± SEM
of n = 20 cells per line from two independent
differentiation experiments. Student’s
t test; *p < 0.001.
(E) A high magnification image reveals
double-membrane vesicles corresponding
to autophagolysosomes, with arrows indi-
cating double membranes.
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neuroblastoma cells, rat primary neurons, andmouse fibro-
blasts (Alvarez-Erviti et al., 2011; Ejlerskov et al., 2013; Em-
manouilidou et al., 2010; Jang et al., 2010; Lee et al., 2013).
We therefore investigated if the autophagic/lysosomal dis-
turbances observed in GBA-N370S dopaminergic neuronal
cultures could alter a-synuclein release in our human PD-
specific cell model. Analysis by ELISA revealed the presence
of a-synuclein in the culture media of differentiated dopa-
minergic cultures, which increased over time (Figure 7B).
Importantly, the levels of a-synuclein in the media were
found to be increased for mature dopaminergic neuronal
cultures differentiated from GBA-N370S patients when
compared with controls (Figure 7C), suggesting a possible
link between the autophagic/lysosomal disturbances we
report and the modulation of a-synuclein release.
The secretion of a-synuclein has been associated with
exosomes in a-synuclein overexpressing neuroblastoma
cells, following an unconventional secretory pathway (Em-
manouilidou et al., 2010). We therefore examined if a
similar mechanism could be associated with a-synuclein
release in our PD patient model. Exosomes were isolated
from dopaminergic neuronal cultures and analyzed by
nanoparticle tracking analysis. This analysis did not reveal
any significant difference in the nodal size of exosomes
between control and GBA-N370S cultures (Figure S6). In
addition, there was no difference in the concentration of
exosomes secreted by control or GBA-N370S dopaminergic
cultures (Figure S6). Western blot analysis of extracted
exosomes confirmed the detection of generic (CD81) and
neuron-specific (L1CAM) exosomal markers, and the
absence of calnexin, an indicator of apoptotic bodies (Fig-
ure 7D). These data indicate that extracellular a-synuclein
is not associated with neuron-derived exosomes. Accord-
ingly, ELISA analysis showed that exosome depletion of
conditioned media did not change the a-synuclein levels
in the media and it was estimated that exosome-associated
a-synuclein constitutes less than about 1.6% of the total
extracellular fraction.
To further investigate themechanisms resulting in a-syn-
uclein release in dopaminergic cultures carrying GBA-
N370Smutation, cells were treated with either chloroquine
(CQ) or with bafilomycin A1, both of which cause impaired
lysosomal function by neutralizing lysosomal pH (Juhasz,
2012). Each treatment resulted in a significant increase in
released a-synuclein in GBA-N370S dopaminergic cultures
(Figure 7E). Both treatments had a bigger impact on patient
cells than controls, suggesting a role for lysosomal function
in a-synuclein release in GBA-N370S dopaminergic cul-
tures. To explore a possible role for the ER/Golgi-dependent
classical export pathway in a-synuclein release, cultures
were treated with brefeldin A, which blocks the trafficking
between ER and Golgi. Brefeldin A treatment resulted in
increased release of a-synuclein in all dopaminergic cul-
tures (Figure 7E), more pronounced in GBA-N370S lines,
suggesting that the ER/Golgi vesicle-mediated transport is
also involved in a-synuclein release. Overall, these data
confirm an increased release of a-synuclein in GBA-N370S
PD dopaminergic neuronal cultures associated with an
impairment of the autophagic/lysosome pathway, offering
a possible therapeutic target.
DISCUSSION
Using human iPSCs derived from PD patients carrying the
heterozygous GBA-N370S mutation, we have identified
relevant mechanisms by which a heterozygous GBAmuta-
tion associated with PDmay increase cellular susceptibility
to disease. Our results highlight an important role of
heterozygous mutant GCase in the disruption of protein
homeostasis in dopaminergic neurons, ultimately leading
to increased a-synuclein release, which may be central for
the early pathogenesis of PD. Differentiation of ten inde-
pendent iPSC lines from three controls and three unrelated
GBA-N370S PD patients into dopaminergic neurons al-
lowed us to robustly investigate this genetic contribution
in an appropriate human model of early PD pathology.
Our data suggest that the heterozygous GBA-N370S mu-
tation results in the retention of GCase within the ER in
PD iPSC-derived dopaminergic neuronal cultures. We
found no evidence of a reduction of GCase protein levels
in our multiple lines derived from three unrelated patients,
indicating that the protein is not targeted for degradation.
We have observed an overall increased expression of
LIMP2, a GCase-specific lysosomal receptor, in dopami-
nergic cultures from GBA-N370S patients. Increased
LIMP2 expression is likely to be part of a cellular response
to GBA mutations, as it has been previously shown that
LIMP2 overexpression increases transportation of ER-re-
tained GCase toward the lysosomes (Reczek et al., 2007).
We observed the upregulation of multiple ER stress
markers in GBA-N370S-derived dopaminergic neuronal
cultures, which likely reflects a dysregulation of the ER
homeostatic environment induced by misprocessing of
misfolded GCase similar to a postmortem analysis of PD
GBA patients showing UPR activation (Gegg et al., 2012).
We have also identified alterations in the autophagy
pathway in our PD model. Levels of autophagosomes
were increased in dopamine neurons from GBA-N370S
lines, and we provide multiple lines of evidence to support
an impairment of general autophagic vacuole clearance.
In addition, multiple lysosomal markers were upregulated
in GBA-N370S dopaminergic lines consistent with an
impairment of lysosomal degradation capacity. More-
over, an enlargement of the lysosomal compartment was
identified, specifically within TH immunogold-identified
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Figure 6. Enlargement of the Lysosomal Compartment in Dopamine Neurons Derived from PD Patients Carrying a Heterozygous
GBA-N370S Mutation
(A–C) Increased protein levels of multiple lysosomal markers in heterozygous GBA-N370S PD dopaminergic cultures. Representative western
blots and quantifications for the expression of: (A) LAMP1, (B) LAMP2A, and (C) cathepsin D. In each case, data represent the mean ± SEM
from performing at least three independent differentiation experiments per line each analyzed in triplicate. Student’s t test; *p < 0.001.
(D) Electron micrographs showing representative images of immunogold-labeled TH-positive neurons for differentiated controls and
GBA-N370S neurons in basal and under starvation conditions. Arrows indicate LAMP1-positive structures of the lysosomal pathway. Scale
bar, 200 nm.
(legend continued on next page)
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dopaminergic neurons derived from patient’s lines, charac-
terized by increased number and size of lysosomal struc-
tures. Lysosomal dysfunction is a key pathological event
in PD (Dehay et al., 2010), and the specificity to dopamine
neuronsmay explain the preferential vulnerability of these
neurons.
Altered cellular lipid composition can be associated with
ER disturbances (Basseri and Austin, 2012) and autophagic
impairments (Koga et al., 2010). Although themechanisms
underlying cellular distribution of GlcCer species in neu-
rons is not well understood, lipid contents are known to
differ in membranes undergoing ER-Golgi maturation or
fusion within various organelles (Halter et al., 2007). The
different GlcCer species distribution observed in our
neuronal cultures between control and GBA-N370S lines
may be due to the different trafficking of GCase. As a result
of altered trafficking, the mutant GCase enzyme may hy-
drolyze a species that might not have been degraded in
normal cells, thereby decreasing total amounts of certain
lipids (e.g., 30% reduction of C20:0 GlcCer levels in GBA-
N370S neurons). On the other hand, reduced GCase con-
centration in particular sub-compartments may promote
the accumulation of other species (e.g., 65% increase in
C16:0 and C24:0 species) in GBA-N370S neurons.
It is known that a-synuclein is degraded in part by the au-
tophagic/lysosomal pathway (Cuervo et al., 2004). We
observed no differences for the intracellular a-synuclein
levels in dopaminergic cultures derived from three patients
carrying the GBA-N370S mutation, which is in line with
the report of Scho¨ndorf et al. (2014). Althoughpostmortem
studies have suggested the possibility of increased intracel-
lular a-synuclein in brains from PD patients carrying GBA
mutations, postmortem tissue likely reflects a much more
advanced stage of disease pathology (Choi et al., 2012;
Gegg et al., 2012).
Since recent reports have demonstrated that perturba-
tions of the autophagic pathway can affect a-synuclein
release in neuroblastoma cells and mouse fibroblasts, we
decided to investigate if a similar mechanism operated in
our physiological human model of PD. Interestingly, we
observed increased levels of a-synuclein released in the
culture media from GBA-N370S dopaminergic neuronal
cultures, which may be a consequence of the autophagic/
lysosomal defects in these cells. To further investigate the
potential mechanisms by which GBA-N370S mutation re-
sults in increased a-synuclein release, dopaminergic cul-
tures were treated with the lysosomal function inhibitors
CQ or bafilomycin A1. Each treatment increased the levels
of released a-synuclein, further suggesting the involve-
ment of the lysosome in the release of a-synuclein in
GBA-N370S dopaminergic cultures. These results suggest
that the autophagic and lysosomal deficits we describe
result in increased a-synuclein release in GBA-N370S dopa-
minergic cultures. The lack of significant increase in
released a-synuclein in control cultures after induced
lysosomal dysfunction suggests a difference in the way
the lysosomes handle a-synuclein between PD and control
cultures. In addition, although earlier reports showed that
a-synuclein release was independent of the ER/Golgi clas-
sical export pathway (Emmanouilidou et al., 2010; Jang
et al., 2010; Lee et al., 2005), recent studies have shown
that in some models, including enteric neurons, a-synu-
clein release is dependent on ER/Golgi exocytosis (Chutna
et al., 2014; Paillusson et al., 2013). Our results indicate
that a-synuclein release is also sensitive to brefeldin A treat-
ment, supporting a role for the ER/Golgi classical pathway
in the release of a-synuclein in both GBA-N370S and
control dopaminergic cultures. Taken together, our data
suggest that a-synuclein release can occur via both conven-
tional and unconventional pathways in dopaminergic
neuronal cultures from GBA-N370S cells.
a-Synuclein release could be an important early event in
the pathology of PD whereby uptake of a-synuclein by
neighboring neurons could result in impaired cellular pro-
teostasis (Desplats et al., 2009). a-Synuclein involvement
in this context might be complex since it was also previ-
ously shown to cause ER stress, block ER-Golgi trafficking
(Cooper et al., 2006), induce lysosomal rupture (Freeman
et al., 2013), decrease lysosomal function (Cuervo et al.,
2004), and inhibit GCase activity (Mazzulli et al., 2011).
Secreted a-synuclein has also been associated with
exosomes in the context of neuroblastoma cells overex-
pressing a-synuclein (Alvarez-Erviti et al., 2011; Emma-
nouilidou et al., 2010). To expand on the observation of
increased a-synuclein release in our model, we extracted
and analyzed human iPSC-derived neuronal exosomes.
We did not find a readily detectable association of a-synu-
clein with exosomes in our model, which is consistent
with our recent proteomic analysis in serum-derivedmicro-
vesicles from PD patients (Tomlinson et al., 2015).
Heterozygous GBA-N370S mutations are the strongest
risk factor for PD and have also been associatedwith related
(E) Quantification of EM data shows an increase number of lysosomes in basal conditions for TH neurons in GBA-N370S cultures compared
with controls.
(F) The lysosomal compartment, represented as a percentage of the cell area occupied by LAMP1-labeled organelles, was also increased in
size in TH-positive neurons in basal conditions in GBA-N370S cultures. In each case, data represent the mean ± SEM of n = 20 cells per line
from two independent differentiation experiments. Student’s t test; *p < 0.001.
See also Figure S5.
352 Stem Cell Reports j Vol. 6 j 342–356 j March 8, 2016 j ª2016 The Authors
Figure 7. Increased Extracellular a-Synuclein in Heterozygous GBA-N370S-Derived Dopaminergic Neuronal Cultures
(A) There is no difference in the intracellular a-synuclein content in dopaminergic neuronal cultures from controls and GBA-N370S PD
lines. Representative western blot and quantification for intracellular a-synuclein levels.
(B) Analysis of culture media by ELISA revealed the presence of a-synuclein, which increased over time.
(C) Levels of extracellular a-synuclein in culture media were higher for heterozygous GBA-N370S dopaminergic cultures when compared
with controls, during maturation, measured by ELISA. Fold change of neurons at day 31–36 compared with early neurons at day 21. In each
case, data represent the mean ± SEM from performing at least three independent differentiation experiments per line each analyzed in
triplicate. Student’s t test; *p < 0.001.
(D) Western blot analysis of culture media extracted exosomes confirmed the expression of CD81 and L1CAM exosomal markers in the
absence of calnexin. Data represent the mean of replicates ± SEM from performing at least three independent differentiation experiments
per line.
(E) Modulation of a-synuclein release in differentiated dopaminergic neurons from control and GBA-N370S dopaminergic cultures by
treatment with CQ, bafilomycin A1, and brefeldin A, measured by the MesoScale Discovery platform. Each bar represents the mean ± SEM of
differentiated lines from at least three independent individuals done in duplicate (n = 6–8). Two-way ANOVA; *p < 0.05; ***p < 0.005;
****p < 0.0001.
See also Figure S6.
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Lewy body disorders, in particular with dementia with
Lewy bodies, where they represent an important risk factor
(Nalls et al., 2013). Dopaminergic neurons of the substantia
nigra are lost in both PD and dementia with Lewy bodies,
which may occur through the mechanisms of altered pro-
tein homeostasis we describe here. Interestingly, although
a GBA mutation increases the relative risk for PD by 30-
fold compared with the general population (McNeill
et al., 2012), most GBA mutation carriers do not develop
disease. This suggests that a GBA mutation confers strong
susceptibility, but that a second hit, likely genetic or envi-
ronmental, is required to drive pathology. Pharmacological
rescue in PD GBA-N370S neurons using chemical chaper-
ones such as isofagomine and ambroxol, or treatment
with recombinant GCase, will allow further dissection
of the mechanisms by which GBA mutations confer sus-
ceptibility to PD and may identify promising protective
therapies.
Taken together, our findings suggest that in PD, the het-
erozygous GBA-N370Smutation leads to the misprocessing
ofGCase, ER stress upregulation, and autophagic/lysosomal
dysfunction in dopaminergic neurons.Wepropose that this
combinationofdisturbances impairsproteinhomeostasis in
dopamine neurons, which leads to increased a-synuclein
release. Such cellular events in combination may lead to
preferential dopamine neuronal vulnerability in PD.
EXPERIMENTAL PROCEDURES
Participant Recruitment
Participants were recruited to this study having given signed
informed consent, which includedmutation screening and deriva-
tion of hiPSC lines from skin biopsies (Ethics Committee: National
Health Service, Health ResearchAuthority, NRESCommittee South
Central, Berkshire, UK, who specifically approved this part of the
study (REC 10/H0505/71).
Culture and Reprogramming of Primary Fibroblasts
Skin punchbiopsies (4mm in diameter) were obtained frompartic-
ipants and low passage fibroblast cultures established and trans-
duced with reprogramming retroviruses (c-MYC, KLF4, SOX2,
OCT3/4, and Nanog). Colonies displaying iPSC morphology
were picked on day 28 and passaged on murine embryonic fibro-
blasts by manual dissection every 5–7 days. Full characterization
information from the PDpatient lines is given in the Supplemental
Experimental Procedures. The control iPSC lines have been
described fully elsewhere (Hartfield et al., 2014; van Wilgenburg
et al., 2013).
RT-PCR, Immunocytochemistry, and Western Blot
Analysis
These procedures were performed using standard methods and
details are given in Supplemental Experimental Procedures. Repre-
sentative western blots for antibodies used are shown Figure S7.
a-Synuclein Measurements
An in-house ELISA for the accurate quantification of a-synuclein
concentration was developed by using two commercially available
a-synuclein-specific antibodies: the monoclonal Syn-1 (BD Trans-
ductions) as the capture antibody and the polyclonal C-20 (Santa
Cruz) as the detection antibody, which was used after its covalent
conjugation with horseradish peroxidase (Emmanouilidou et al.,
2011). MesoScale Discovery assays were used following the manu-
facturer’s instructions. Further details are given in the Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
The SNP datasets and the Illumina HT12v4 transcriptome array re-
sults have been deposited in Gene Expression Omnibus under
accession number GEO: GSE53426.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and one table and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2016.01.013.
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